Edwards Lifesciences Balans Gezondheid
Financiële gezondheid criteriumcontroles 6/6
Edwards Lifesciences heeft een totaal eigen vermogen van $9.6B en een totale schuld van $597.5M, wat de schuld-eigenvermogensverhouding op 6.2% brengt. De totale activa en totale passiva bedragen respectievelijk $13.0B en $3.4B. De EBIT Edwards Lifesciences is $1.9B waardoor de rentedekking -28.5 is. Het heeft contanten en kortetermijnbeleggingen van $4.4B.
Belangrijke informatie
6.2%
Verhouding schuld/eigen vermogen
US$597.50m
Schuld
| Rente dekkingsratio | -28.5x |
| Contant | US$4.45b |
| Aandelen | US$9.61b |
| Totaal verplichtingen | US$3.36b |
| Totaal activa | US$12.97b |
Recente financiële gezondheidsupdates
Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?
Jun 24
Here's Why Edwards Lifesciences (NYSE:EW) Can Manage Its Debt Responsibly
Jan 28Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?
Oct 23Recent updates
Estimating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Nov 11Edwards Lifesciences Q3: Divesting Critical Care And Focusing On Structural Hearts
Oct 25Bearish: Analysts Just Cut Their Edwards Lifesciences Corporation (NYSE:EW) Revenue and EPS estimates
Sep 11Capital Investments At Edwards Lifesciences (NYSE:EW) Point To A Promising Future
Aug 30Is Now The Time To Look At Buying Edwards Lifesciences Corporation (NYSE:EW)?
Aug 17Edwards Lifesciences Q2: Buy The Dip Amid Guidance Cut
Jul 26Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Jul 26Why Investors Shouldn't Be Surprised By Edwards Lifesciences Corporation's (NYSE:EW) P/E
Jul 12Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?
Jun 24Edwards Lifesciences Corp Looks Bullish (Technical Analysis)
Jun 22Capital Investments At Edwards Lifesciences (NYSE:EW) Point To A Promising Future
May 13Edwards Lifesciences: EPS Acceleration, Shares Poised To Rally (Rating Upgrade)
May 09When Should You Buy Edwards Lifesciences Corporation (NYSE:EW)?
Apr 29Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Apr 15Edwards Lifesciences Corporation's (NYSE:EW) Popularity With Investors Is Clear
Apr 01Edwards Lifesciences' (NYSE:EW) Soft Earnings Don't Show The Whole Picture
Feb 21Edwards Lifesciences: EVOQUE FDA Approval; Critical Care Spin-Off (Rating Maintained)
Feb 14Edwards Lifesciences Corporation (NYSE:EW) Released Earnings Last Week And Analysts Lifted Their Price Target To US$90.47
Feb 08Here's Why Edwards Lifesciences (NYSE:EW) Can Manage Its Debt Responsibly
Jan 28The Returns At Edwards Lifesciences (NYSE:EW) Aren't Growing
Jan 14Edwards Lifesciences: Undervalued With A Substantial Upside Potential
Jan 09Edwards Lifesciences Corporation's (NYSE:EW) Share Price Not Quite Adding Up
Dec 31Calculating The Fair Value Of Edwards Lifesciences Corporation (NYSE:EW)
Dec 17Edwards Lifesciences: Sector Derating A Bigger Threat Than Competition Or Slowing Markets
Oct 26Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?
Oct 23Is Now The Time To Look At Buying Edwards Lifesciences Corporation (NYSE:EW)?
Oct 09Edwards Lifesciences (NYSE:EW) Is Reinvesting To Multiply In Value
Sep 26A Look At The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Sep 11Edwards Lifesciences: Rising Dominance In Structural Heart Disease
Aug 21Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( $6.7B ) EW } overtreffen de korte termijn passiva ( $1.9B ).
Langlopende schulden: De kortetermijnactiva EW ( $6.7B ) overtreffen de langetermijnschulden ( $1.4B ).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: EW heeft meer geld in kas dan de totale schuld.
Schuld verminderen: De schuld/eigen vermogen-ratio van EW is de afgelopen 5 jaar gedaald van 15.6% naar 6.2%.
Schuldendekking: De schuld van EW wordt goed gedekt door de operationele kasstroom ( 135% ).
Rentedekking: EW verdient meer rente dan het betaalt, dus de dekking van rentebetalingen is geen probleem.